A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to
determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended
phase II dose (RP2D) of SHR-A1912.